Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||PLX4720 + TAK-632|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PLX4720||PLX-4720|PLX 4720||BRAF Inhibitor 21||PLX4720 is a 7-azaindole derivative and RAF kinase inhibitor with greater affinity for BRAF V600E than BRAF wild-type, which may induce cell cycle arrest and apoptosis, and lead to tumor growth inhibition and regression (PMID: 18287029).|
|TAK-632||TAK 632|TAK632||RAF Inhibitor (Pan) 23||TAK-632 is an inhibitor of Raf, which has been shown to suppress the kinase activity of the Raf dimer thereby resulting in diminished paradoxical activation of Raf (PMID: 24121489, PMID: 31734178).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||colorectal cancer||sensitive||PLX4720 + TAK-632||Preclinical - Cell line xenograft||Actionable||In a preclinical study, PLX4720 and TAK-632 combination treatment resulted in durable inhibition of Erk signaling and tumor growth in xenograft models of colorectal cancer cells harboring BRAF V600E (PMID: 27523909).||27523909|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|